Special Issue

The Tumor–Immune Interface for Next-Generation Immunotherapy

Message from the Guest Editor

Next-generation immunotherapies aim to modulate the tumor–immune interface by either enhancing anti-tumor immune responses or inhibiting immunosuppressive mechanisms. Overall, the tumor–immune interface is a complex and dynamic system that plays a crucial role in tumor progression and response to immunotherapy. Developing next-generation immunotherapies that can effectively modulate the tumor–immune interface is an active area of research and holds promise for improving outcomes for cancer patients. This Special Issue of *Cancers* therefore encompasses original research articles and comprehensive reviews on all aspects of the tumor–immune interface for next-generation immunotherapy.

Guest Editor

Dr. Ziliang Huang

Molecular Engineering for Cellular Imaging and Reprogramming, University of Southern California, Los Angeles, CA, USA

Deadline for manuscript submissions

closed (30 September 2024)

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/si/166044

Cancers
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
cancers@mdpi.com

mdpi.com/journal/cancers

Cancers

an Open Access Journal by MDPI

Impact Factor 4.4
CiteScore 8.8
Indexed in PubMed

mdpi.com/journal/cancers

MDPI

About the Journal

Message from the Editor-in-Chief

Cancers is an international online journal addressing both clinical and basic science issues related to cancer research. The journal is publishing in Open Access format, which will certainly evolve to ensure that the journal takes full advantage of the rapidly changing world of information and knowledge dissemination. It publishes high-quality clinical, translational, and basic science research on cancer prevention, initiation, progression, and treatment, as well as other related topics, particularly to capture the most seminal studies in the rapidly growing area of immunology, immunotherapy, and tumor microenvironment.

Editor-in-Chief

Prof. Dr. Samuel C. Mok
Department of Gynecologic Oncology and Reproductive Medicine, The University of Texas MD Anderson Cancer Center, Houston, TX 77030, USA

Author Benefits

Open Access:

free for readers, with article processing charges (APC) paid by authors or their institutions.

High Visibility:

indexed within Scopus, SCIE (Web of Science), PubMed, PMC, Embase, CAPlus / SciFinder, and other databases.

Journal Rank:

JCR - Q2 (Oncology) / CiteScore - Q1 (Oncology)